Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 8/20 | 0.41 |
| ▸ | MGAM | O43451 | 4/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 10/20 | 0.32 |
| ▸ | UGCG | Q16739 | 3/20 | 0.32 |
| ▸ | SI | P14410 | 2/20 | 0.32 |
| ▸ | AGL | P35573 | 2/20 | 0.32 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22220484 | 0.73 | GAA (0.48) | GAAMGAMGBA2UGCGSI | |
| SCHEMBL31737790 | 0.71 | GAA (0.42) | GAAMGAMGBA1 | |
| SCHEMBL25753278 | 0.69 | GAA (0.67) | GAAMGAMGBA2UGCGSI | |
| SCHEMBL25753279 | 0.69 | GAA (0.67) | GAAMGAMGBA2UGCGSI | |
| SCHEMBL85752 | 0.66 | GAA (0.42) | GAAMGAMGBA1 | |
| SCHEMBL14818704 | 0.65 | — | — | |
| SCHEMBL16190162 | 0.65 | — | — | |
| SCHEMBL12616612 | 0.64 | — | — | |
| SCHEMBL25076449 | 0.63 | — | — | |
| SCHEMBL17972950 | 0.63 | GAA (0.63) | GAAMGAMGBA2UGCGSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | GAA 1989/4885MGAM 2954/4885GBA2 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.